Osivax
Latest round
- Series A
Last raised
- Mar 2019
Total raised
- $3.5M
Investors
- 4
About Osivax
Founded in 2017 and headquartered in Lyon, France, Osivax SAS specializes in biotechnology aimed at vaccine development. The company was founded by Alexandre Le Vert, who has a background in biotech ventures.Osivax specializes in developing a new class of universal vaccines aimed at providing long-term protection against highly mutating viruses. Their core technology, oligoDOM, utilizes self-assembling nanoparticles designed to elicit strong T-cell immune responses against conserved internal antigens of viruses. This technology is particularly beneficial for addressing the challenges posed by rapidly evolving influenza and coronavirus strains. The flagship product, OVX836, has progressed through Phase 1 and Phase 2a clinical trials, demonstrating a solid safety profile and promising efficacy signals.40 for the same year. The company aims to enhance its product offerings and is targeting expansion into new markets, with specific plans to broaden its reach in the global healthcare sector.
Who invested in Osivax
4 investors across 1 round
See all investors in Osivax
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 15, 2019
Amount
$3.5M
Investors
Questions about Osivax
Who invested in Osivax?
Osivax has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Osivax raised?
Osivax has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Osivax last raise money?
Osivax's most recent round on record is a Series A, in Mar 2019.
What does Osivax do?
Founded in 2017 and headquartered in Lyon, France, Osivax SAS specializes in biotechnology aimed at vaccine development.
Where is Osivax headquartered?
Osivax is headquartered in Lyon, France.
Which VCs invest in companies like Osivax?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Osivax's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Osivax? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.